Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q1 2022 · 10-Q
Revenue$666.00K$666.00K±0.0% vs Q1 2021 Net Income-$10.71M-$10.71MN/M vs Q1 2021 EPS Diluted$0.27$0.27no prior Q1 2021 on file Operating Income-$11,252,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,172,000N/M Margins · derivedOperating margin-1689.5%−697.9 pt vs Q1 2021
Net margin-1607.8%−697.4 pt vs Q1 2021
ended Mar 31, 2022 · filed May 12, 2022 · 42 d after period end